New record: GPHL ranked 155th among China Top 500 Enterprises
2020-10-09 10:35:56 GPHL GPHL
On September 28th, the 2020 list of China’s top 500 enterprises was published in Zhengzhou, capital city of Henan province. GPHL ranked 155th with an annual revenue of 133 billion RMB, up 5 places from last year. On the list of China Top 500 Enterprises in Manufacturing Sector, GPHL ranked 61th, up 3 spots from last year. It also ranked 10th on Top 100 Leaders in Strategic and Emerging Industries in China.
In 2019 GPHL achieved sales revenues of 133 billion RMB and a total profit of 5 billion RMB, up 15% and 21% respectively on a year-over-year basis. With sustained double-digit growth in recently years, GPHL has climbed ranks of China’s top 500 enterprises and claimed the top spot on China’s Top 100 Pharmaceutical Companies for consecutive years. It was also included into the ‘"double-hundred action’ for SOE reform.
GPHL is uniquely well-positioned in the field of vaccine development and industrialization as it has a team of top talents, including 3 Nobel laureates, 20 academicians and doctors with the title of ‘Great Master of Chinese Medicine’ and more than 100 doctoral and post-doctoral researchers. GPHL has 10 national research institutions, 14 provincial enterprise technology centres, 21 provincial engineering technology centres. It won a second prize in the State Technological Invention Award, two second prizes in the State Science and Technology Progress Award and has earned more than 40 Guangdong Science and Technology Prizes.
Authors: Monica & Michelle
Editors: Olivia & Jerry